Xtant Medical Holdings, Inc. (NYSE American: XTNT) – Key Investor Insights from 2025 Annual Report

Overview

Xtant Medical Holdings, Inc. (“Xtant Medical” or the “Company”), a provider of regenerative medicine products and medical devices, has released its Annual Report for the fiscal year ended December 31, 2025. The report contains several significant disclosures and risk factors that shareholders and potential investors should carefully consider, as these may have a material impact on the Company’s share price and future prospects.

Key Financial and Operational Highlights

• Net Income Achieved in 2025: Xtant Medical reported net income for the year ending December 31, 2025. However, the Company has a history of significant losses and warns that despite its focus on sustaining profitability, it may not achieve sustained profitability in the future.
• One-Time License Revenue in 2025: The Company recognized a significant amount of license revenue in 2025, which is not expected to repeat in 2026. The anticipated loss of this revenue stream could adversely impact 2026 revenues, gross margins, and overall financial performance.
• Market Value and Share Statistics: As of June 30, 2025, the aggregate market value of common stock held by non-affiliates was approximately \$45 million. As of March 25, 2026, there were 140,068,260 shares of common stock outstanding.
• Listing Information: Xtant Medical’s common stock (par value \$0.000001 per share) is listed on the NYSE American under the symbol “XTNT.”
• Company Status: Xtant Medical is classified as a “Non-accelerated filer” and a “Smaller reporting company,” which means it is subject to scaled disclosure requirements.

Risks and Factors That May Affect Shareholder Value

• Revenue Volatility: The Company anticipates that the loss of substantial license revenue recognized in 2025 will negatively affect 2026 financial results, including gross margins. This is a potentially price-sensitive issue for investors who may expect growth or stability in revenue.
• Ongoing Losses Despite Recent Profitability: While Xtant Medical posted a profit in 2025, management cautions that it has historically incurred losses and may continue to do so, which could dampen investor expectations for future profitability.
• Inflation, Tariffs, and Supply Chain Disruptions: Persistent inflation, tariffs, and global supply chain disruptions are cited as risks that could delay product launches, reduce revenues, increase costs, and squeeze profit margins.
• Competition: The Company faces intense competition in its sector, which could impact its market share and profitability.
• Private Label and OEM Channel Fluctuations: Xtant’s private label and original equipment manufacturer (OEM) channels are subject to significant fluctuation, posing risks to consistent revenue streams.
• Acquisition and Disposition Risks: The Company acknowledges risks associated with prior and future acquisitions, dispositions, or business combinations, which could adversely affect results.
• Product Liability: Xtant may face expensive product liability litigation, which could materially impact financial performance.
• Quarterly Volatility: The Company’s quarterly results are subject to substantial fluctuations, making future performance unpredictable.
• Limitations on Use of NOLs: There are limitations on the Company’s ability to use net operating loss carryforwards to offset future taxable income.
• Material Weakness in Internal Controls: Notably, Xtant Medical identified a material weakness in its internal control over financial reporting as of December 31, 2025. This is a critical issue for investors as it may affect the reliability of the Company’s financial statements.
• Product Risks and Regulatory Issues: The Company faces risks related to product misuse, potential recalls, and the need for regulatory compliance. Any incidents could result in litigation, increased costs, and damage to reputation.
• Coverage and Reimbursement Risks: Xtant’s revenues depend on prompt and adequate insurance coverage and reimbursement from both public and private insurers.
• Human Capital Risks: The Company has limited staffing and is dependent upon key employees. Competition for qualified workers is intense.
• Intellectual Property Risks: There are risks related to the Company’s ability to obtain or protect proprietary rights. Failure to do so could result in loss of market share and profitability.
• Information Technology and Cybersecurity: Xtant is dependent on various IT systems. Failures, interruptions, or tampering could have a material adverse effect on operations.
• Indebtedness and Liquidity: The Company has existing indebtedness that may be difficult to repay, replace, or restructure if needed. Xtant may require additional financing to satisfy future liquidity requirements.
• Shareholder Concentration: Funds affiliated with Nantahala Capital Management, LLC own a significant percentage of the Company’s common stock, allowing them to exert control over matters subject to shareholder approval.
• Stock Price Volatility and Potential Dilution: The Company’s share price is noted to be extremely volatile, and there is risk of dilution from potential future issuances of additional common stock.
• General Global Risks: The Company is subject to general risks including worldwide economic instability, social unrest, and other macroeconomic factors.

Corporate Governance and Compliance

• Regulatory Compliance: The Company confirms ongoing compliance with the Foreign Corrupt Practices Act (FCPA) and similar anticorruption laws in other jurisdictions. It is also subject to the Federal Physician Payments Sunshine Act and other state and federal regulations affecting device manufacturers.
• File Status and Controls: Xtant Medical is not a well-known seasoned issuer, is not a voluntary filer, and has filed all required reports in the last 12 months. However, as noted above, a material weakness in internal control over financial reporting has been identified.
• Employee Base: As of December 31, 2025, the Company had 151 full-time employees, with a breakdown across operations, sales/marketing, research/development, regulatory/quality, and administration.

Forward-Looking Statements and Cautionary Notes

The report contains numerous forward-looking statements, with management cautioning that these are subject to significant risks, uncertainties, and assumptions. Investors are reminded that actual results may differ materially from those projected.

Conclusion

Potential Share Price Sensitivity: The combination of one-time license revenue in 2025, a newly identified material weakness in internal controls, anticipated revenue declines in 2026, and ongoing operational and regulatory risks are all material factors that could significantly impact Xtant Medical’s share price. Investors are urged to monitor developments closely, especially regarding any remediation of the internal control weakness and the Company’s ability to generate recurring revenue and profits in 2026 and beyond.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should review the full Annual Report and consult with a qualified financial advisor before making any investment decisions. The financial performance and risk factors highlighted are subject to change and may not represent all risks faced by Xtant Medical Holdings, Inc.

View Xtant Medical Holdings, Inc. Historical chart here